Designed to Fight Resistance Where Conventional Antibiotics Fail
Elores provides a clinically significant Carbapenem-sparing option
Elores is a novel patented Antibiotic Adjuvant Entity containing a beta-lactam antibiotic, a beta-lactamase inhibitor and an Antibiotic Resistance Breaker (ARB).
It is a novel combination of Ceftriaxone (third generation beta-lactam cephalosporin), Sulbactam (beta-lactamase inhibitor) and Disodium EDTA (Class 1 Antibiotic Resistance Breaker), and it restores the in vitro activity of Ceftriaxone against ESBL/MBL producing gram-negative bacteria, including enzyme families that belong to Ambler class A (TEM, SHV, CTX-M), class B (NDM, VIM, IMP),
How Elores Works
Broad-Spectrum Antibacterial Action
The bactericidal activity of ceftriaxone results from inhibition of mucopeptide synthesis in the bacterial cell wall. Ceftriaxone exerts in vitro activity against a wide range of gram-negative and gram-positive micro-organisms.
Although ceftriaxone is stable to most beta-lactamases, both penicillinases and cephalosporinases, many extended-spectrum beta-lactamase (ESBL) and metallo-beta-lactamase (MBL) producing strains continue to develop resistance.
Breaking Resistance Mechanisms
EDTA is a non-antibiotic adjuvant entity that has no antibiotic activity of its own. However, when administered with antibiotics, it exhibits pharmacological activity through its catalytic action.
It helps reduce efflux transporter expression, inhibits curli formation, and aids in bacterial biofilm eradication by preventing biofilm formation and making existing biofilms more porous through divalent ion chelation.
Additionally, Disodium EDTA helps open porin channels, allowing more drugs to enter the periplasmic space and resulting in enhanced bacterial killing.
Protecting the Antibiotic
Sulbactam is a beta-lactamase inhibitor that is administered with beta-lactam antibiotics to inhibit beta-lactamase, the enzyme produced by bacteria that destroys antibiotics. It irreversibly binds to beta-lactamase and prevents it from interacting with ceftriaxone.
Sulbactam not only potentiates the bactericidal activity of beta-lactam antibiotics, but also exhibits moderate antibacterial activity of its own. By forming a protein complex with beta-lactamases, sulbactam irreversibly blocks their destructive hydrolytic activity, thereby extending the activity spectrum of ceftriaxone.
The Elores Synergy
Elores, comprising Ceftriaxone, Disodium Edetate, and Sulbactam for infusion, is a synergistic antimicrobial antibiotic adjuvant entity with marked in vitro antibacterial activity against a broad spectrum of ESBL-producing microorganisms
Clinical Relevance
Elores is indicated in the management of serious resistant Gram-negative infections, especially in critical care settings.
It has shown relevance in:
- Complicated urinary tract infections
- Acute pyelonephritis
- Severe hospital-acquired infections
- Resistant infections where conventional therapies may no longer be effective
Why Elores Matters in the Fight Against AMR
Antimicrobial resistance is one of the fastest-growing global health threats. Increasing resistance among Gram-negative bacteria has made many conventional antibiotics less effective, creating an urgent need for innovative therapies.
As antimicrobial resistance continues to grow globally, the need for therapies that can address resistant infections has never been greater. Elores was developed to meet this challenge.
By combining an antibiotic, a beta-lactamase inhibitor and an antibiotic resistance breaker in a single formulation, Elores represents a research-based response to the growing burden of antimicrobial resistance.
Milestones That Define Elores
Over the years, Elores has earned recognition for its innovation, research strength and growing global relevance.
- Approved and launched in India in 2013.
- Received a Japanese patent, strengthening its international intellectual property footprint.
- Awarded a Gold Medal for innovation for its contribution to anti-infective therapy.
- Received industry recognition and awards for innovation in healthcare.
- Acquired by Cipla in 2019 for the Indian market.
- Expanded internationally across multiple countries.
Elores Across Borders
From India to international markets, Elores continues to expand its reach in the global fight against antimicrobial resistance.